GT Biopharma Q1 EPS $(1.64) Beats $(2.70) Estimate
Portfolio Pulse from Benzinga Newsdesk
GT Biopharma (NASDAQ:GTBP) reported a Q1 EPS of $(1.64), beating the analyst consensus estimate of $(2.70) by 39.26%. This represents a significant decrease compared to the $(0.21) loss per share from the same period last year.
May 15, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GT Biopharma reported a Q1 EPS of $(1.64), beating the analyst consensus estimate of $(2.70) by 39.26%. However, this is a significant decline from the $(0.21) loss per share reported in the same period last year.
The better-than-expected EPS is a positive short-term indicator for GTBP's stock price, despite the significant year-over-year decline. Beating analyst estimates often leads to a positive market reaction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100